MCP Announces Multi-Year Contract Manufacturing Agreement

MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement

PARSIPPANY, NJ JUNE 29, 2010 MCP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectables, vaccines, ophthalmics and otics announced today that it has entered into a multi-year contract supply agreement with an undisclosed ophthalmic company. Under terms of the agreement, MCP will be responsible for manufacturing and supply of a proprietary ophthalmic product, which is targeted for launch next year. Stuart Hinchen co-founder and president of MCP stated, “We are very pleased that MCP was chosen for this large-scale multi-year contract.

Our knowledgeable staff, approach to technology transfer and cGMP compliance record with the FDA, EMEA and ANVISA allows us to serve this important customer. We have a long history of successful partnerships, manufacturing both commercial products and products in development with experience taking products from clinical trial supplies to commercial manufacturing.”

About MCP Pharmaceuticals, LLC MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectable products for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and 44,000 sq. ft. warehouse.

The production facility utilizes five high-speed filling lines and seven lyophilizers. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical or large-scale commercial products. MCP employs more than 330 staff in the USA in its manufacturing, sales & marketing and corporate areas. For more information, please visit jhppharma.com


Additional Press Releases

 

 

07/25/11
MCP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug
Webpage | PDF Format

 

 

 

07/06/11
MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug
Webpage | PDF Format

 

 

07/05/11
MCP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
Webpage | PDF Format

 

 

06/24/11
MCP Pharmaceuticals Announces Chief Executive Officer Succession
Webpage | PDF Format

 

 

03/28/11
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format

 

 

02/24/11
MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format

 

 

01/27/11
MCP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format

 

 

06/29/10
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format

 

 

05/10/10
MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits
Webpage | PDF Format

 

 

09/28/09
MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
Webpage | PDF Format

 

 

08/20/08
MCP Pharmaceuticals & SpePharm complete purchaseof Dantrium® (dantrolene sodium)
Webpage | PDF Format

 

 

07/16/07
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP Pharmaceuticals
Webpage | PDF Format

 

Return To Press & News »